Treatment of migraine with monoclonal antibodies
Source : https://www.tandfonline.com/doi/abs/10.1080/14712598.2022.2072207?journalCode=iebt20
ABSTRACT In the few last years, a new family of drugs, anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs), has been developed for migraine therapy. Anti-CGRP mAbs are highly effective, but...
Expert opinion: Thanks to new research focused on the pathophysiology of migraine, and the discovery that CGRP plays a key role in its etiopathogenesis, new drugs targeting CGRP have been developed. These drugs have led to a paradigm shift, anticipating new and stimulating possibilities in migraine treatment. While physicians and patients are...
-
Dr Hamid4yrAnti-CGRP mAbs have proven to be an effective therapy in the preventive treatment of migraine, achieving a 50% reduction in days of migraine
-
Huma Sheikh, CEO, NY Neurology Medicine, PC4yrGood review paper.
Drug Safety in Episodic Migraine Management in Adults. Part 2: Preventive Treatments - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35587859/
doi: 10.1007/s11916-022-01051-9. Online ahead of print. 1 Geisinger Health Systems, Neurology, 1000 E. Mountain Boulevard, Wilkes-Barre, PA, 18711, USA. [email protected]. 2 Ayer Neurosciences Institute, Hartford HealthCare Medical Group, University of...
Conclusion/Relevance: This review highlights safety concerns of commonly used migraine prophylactic agents and offers suggestions on how to mitigate those risks.
-
Dr Hamid4yrInteresting read that aid in decision-making when choosing safe and effective options for preventive migraine medications.
Recognizing vestibular migraine - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35543531/
Vestibular migraine is a recently defined disorder that is underrecognized by clinicians across specialties. Acute attacks cause symptoms of migraine headaches as well as vestibular symptoms such as dizziness or...
Relevance: Vestibular migraine is a recently defined disorder that is underrecognized by clinicians across specialties. Acute attacks cause symptoms of migraine headaches as well as vestibular symptoms such as dizziness or vertigo. Further research is needed to determine the pathophysiology of vestibular migraine. No consensus treatment...
-
Huma Sheikh, CEO, NY Neurology Medicine, PC4yrThis is such a difficult condition to diagnose and treat.
Twelve-month safety, tolerability and susceptibility to adverse events of prophylactic migraine therapy with erenumab: a retrospective real-world study - The Journal of Headache and Pain
Source : https://thejournalofheadacheandpain.biomedcentral.com/articles/10.1186/s10194-022-01426-8
Background Erenumab is a monoclonal antibody (mAb) against the calcitonin gene related peptide (CGRP) receptor and is commonly used in migraine prophylaxis. Pivotal and open-label studies show a good safety...
Conclusions: By adopting this 'one brain, one life, one approach' strategy in cooperation with partner societies, international organisations, and policymakers, a significant number of neurological disorders may be prevented while enhancing the overall well-being of individuals by maintaining brain health through the life course.
-
Huma Sheikh, CEO, NY Neurology Medicine, PC4yrI find this study really intriguing.
Twelve-month safety, tolerability and susceptibility to adverse events of prophylactic migraine therapy with erenumab: a retrospective real-world study - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35538414/
doi: 10.1186/s10194-022-01426-8. 1 Department of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), West German Headache Center, University Hospital Essen, University Duisburg-Essen, Hufelandstr. 55, 45147, Essen, Germany. 2...
Conclusion: In general, erenumab is well tolerated up to a treatment interval of 12 months and reported AEs rarely lead to discontinuation of therapy. A higher dosage does not increase the patient reported AEs. Furthermore, no habituation of AEs is observed. Nevertheless, females and patients with aura seem to be more prone to have AEs.